Immunovia launches new website today
LUND, Sweden - Immunovia is inviting visitors to explore its newly redesigned website -www.immunovia.com. The new website has been created to provide visitors detailed, extensive and up to date information about Immunovia´s core technology, IMMray™ and its first test for early diagnosis of pancreatic cancer, IMMray™ PanCan-d.
On the new website, visitors can also stay informed with the latest news of the company, and access the financial reports in just one click. The website also has a comprehensive investor section with updated company news and events, financial information and corporate governance information.
Furthermore, the new website introduces Immunovia´s main workflows: IMMray™ microarray technology, IMMray™ microarray production process and IMMray™ Dx Laboratories.
"We are excited about our new website launch and the robust information it provides for customers, investors, partners and media," said Mats Grahn, CEO, Immunovia. "We believe that this new site will allow our visitors to have a very informative experience as we continue to grow and increase our market presence."
Welcome to visit us at www.immunovia.com.
Please give us your feedback on the new website by posting a comment on our Contact us form.
For more information, please contact:
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
SE-223 81 Lund